Adamis Pharmaceuticals Corporation Deferred Revenue 2011-2025 | ADMP

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Adamis Pharmaceuticals Corporation

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
27.8 K	100 K	100 K	916 K	1.01 M	14.8 K	54.5 K	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.01 M	14.8 K	318 K

Quarterly Deferred Revenue Adamis Pharmaceuticals Corporation

2023-Q3	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
173 K	27.8 K	27.8 K	27.8 K	100 K	100 K	100 K	100 K	104 K	121 K	100 K	100 K	100 K	100 K	116 K	116 K	116 K	916 K	1.01 M	1.01 M	1.01 M	1.01 M	14.8 K	14.8 K	10.9 K	14.8 K	54.5 K	54.5 K	54.5 K	54.5 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.01 M	10.9 K	229 K

Deferred Revenue of other stocks in the Drug manufacturers industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
Assertio Holdings ASRT	200 K	$ 0.73	-3.54 %	$ 51.9 M	USA
Aerie Pharmaceuticals AERI	85.4 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	49 K	-	7.5 %	$ 6.35 M	USA
Aurora Cannabis ACB	27 M	$ 5.17	-4.22 %	$ 86.3 M	Canada
Catalent CTLT	250 M	-	-	$ 11.5 B	USA
HEXO Corp. HEXO	8.21 M	-	2.45 %	$ 38.1 M	Canada
DURECT Corporation DRRX	545 K	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	6 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	600 K	-	-	$ 28.9 M	Irlanda
Emergent BioSolutions EBS	27.2 M	$ 12.03	5.34 %	$ 616 M	USA
Pacira BioSciences PCRX	102 K	$ 26.7	1.56 %	$ 1.23 B	USA
Athenex ATNX	2.82 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	114 K	$ 21.39	0.14 %	$ 2.04 B	France
Rockwell Medical RMTI	46 K	$ 0.87	-5.71 %	$ 20.3 M	USA
Evolus EOLS	14.5 M	$ 7.18	1.92 %	$ 445 M	USA
Harrow Health HROW	75 K	$ 45.82	-2.64 %	$ 1.49 B	USA
Sonoma Pharmaceuticals SNOA	641 K	$ 3.51	-2.11 %	$ 4.36 M	USA
China Pharma Holdings CPHI	162 K	$ 1.55	-0.26 %	$ 27.1 M	China
Bausch Health Companies BHC	26 M	$ 6.88	-0.65 %	$ 2.51 B	Canada
Veru VERU	400 K	$ 2.44	0.83 %	$ 329 M	USA
Cumberland Pharmaceuticals CPIX	207 K	$ 3.05	20.47 %	$ 42.9 M	USA
cbdMD YCBD	503 K	$ 1.39	13.52 %	$ 5.99 M	USA
Solid Biosciences SLDB	10.4 M	$ 5.81	-1.11 %	$ 237 M	USA
Perrigo Company plc PRGO	122 M	$ 12.86	-2.17 %	$ 1.77 B	USA
ProPhase Labs PRPH	2.5 M	$ 0.12	0.17 %	$ 1.9 M	USA
Radius Health RDUS	1 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	543 K	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	160 K	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	1.19 M	$ 0.64	-1.25 %	$ 30.6 M	USA
Tilray TLRY	23.7 M	$ 11.6	-4.56 %	$ 7.17 B	Canada
TherapeuticsMD TXMD	523 K	$ 1.69	-3.43 %	$ 17.6 M	USA
Zomedica Corp. ZOM	276 K	-	-0.21 %	$ 98 M	USA